Dr. John Blenis

Cancer cells can disrupt a metabolic pathway that breaks down fats and proteins to boost the levels of a byproduct called methylmalonic acid, thereby driving metastasis, according to research led by scientists at Weill Cornell Medicine.

The greatly increased risk of cancer and cancer mortality with aging may be due in part to the buildup in the body of a key cancer-promoting molecule, according to new preclinical research from scientists at Weill Cornell Medicine.

A change in the protein composition of chromatin—the condensed, packaged form of DNA in the nucleus—boosts the expression of metastasis-related genes; blocking this change appears to stop tumor cells from forming new tumors in mice, suggests a study by Weill Cornell Medicine investigators. 

Weill Cornell Medicine faculty members honored with annual awards at Convocation and Commencement for their exemplary achievements.

Dr. Gina Lee, a former postdoctoral fellow in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine who has now joined the institution’s faculty, has won a 2019 Tri-Institutional Breakout Award for Junior Investigators.

A signaling pathway in cells that regulates fat production could become a new target for cancer drugs, according to a finding by Weill Cornell Medicine researchers.